Company Snapshot Home > Equity > Corporate Information > Company Snapshot
|
|
| Stock Price Details |
|
Chart |
|
|
Last Price (RS)
|
252.60
|
|
Change (%)
|
16.55 (7.01%)
|
|
Best Buy (RS)
|
0(x0)
|
|
Best Sell (RS)
|
0(x0)
|
|
Today's Range (RS)
|
237.20
-
253.80
|
|
52-Week Range (RS)
|
156.00
-
270.60
|
|
Beta (1 Year)
|
1.09
|
|
|
|
|
|
| Index Details |
| BSE HC, BSE SmallCap |
| News |
|
Corporate Details |
| Marksans Pharma to acquire Netherlands-based QliniQ B.V. |
| Indices witness profit booking; PSU Bank shares snap 5-day rally |
| Board of Marksans Pharma recommends final dividend |
| Marksans Pharma consolidated net profit rises 63.59% in the March 2026 quarter |
| Marksans Pharma soars after Q4 PAT jumps 64% YoY |
| Marksans Pharma grants 3 lakh stock options under ESOS |
| Marksans Pharma to convene board meeting |
| Marksans Pharma gains after Q3 PAT rises 8% YoY to Rs 113 crore |
| Marksans Pharma consolidated net profit rises 8.26% in the December 2025 quarter |
| Marksans Pharma incorporates two subsidiaries in Ireland and Canada |
|
|
|
| Incoporation Year : 1992 |
| Chairman : Mark Saldanha |
| Ownership Group : Indian Private |
| Sector : MAN |
| Industry : Pharmaceuticals - Indian - Formulations |
| Registered Office |
Marksans Pharma Ltd
11th Flr GRANDEUR Oshiwara,
Veera Desai Extn Rd Andheri(W),
Mumbai,
Maharashtra-400053 |
Phone:91-22-40012000
Fax:91-22-40012011 |
| E-Mail : companysecretary@marksanspharma.com ; info@marksan |
| URL : http://www.marksanspharma.com |
|
| Investor Returns |
|
| |
Date |
Price |
Returns (%) |
| 1Week |
02-Jun-2026 |
240.90 |
4.86 |
| 1Month |
11-May-2026 |
203.20 |
24.31 |
| 3Month |
09-Mar-2026 |
168.45 |
49.96 |
| 6Month |
09-Dec-2025 |
190.10 |
32.88 |
| 1Year |
09-Jun-2025 |
253.10 |
-0.20 |
|
|
|
|
| Mutual Funds Holding |
|
| Scheme Name |
% Holding |
Market Value (Rs Cr.) |
| UTI-Small Cap Fund |
1.59 |
78.93 |
| Bandhan Small Cap Fund |
0.26 |
65.09 |
| UTI-Aggressive Hybrid Fund |
0.84 |
54.60 |
| UTI-Large & Mid Cap Fund |
0.87 |
51.85 |
| Kotak Special Opportunites Fund |
3.40 |
48.52 |
|
|
|
|
| Groups : Pharmaceuticals - Indian - Formulations |
|
| Company |
Last Price |
Change (%) |
52Week High |
52Week Low |
Market Cap (Rs Cr.) |
| Torrent Pharmaceuticals Ltd |
4,472.95 |
1.38 |
4,714.50 |
3,139.50 |
151,384.95 |
| Gland Pharma Ltd |
2,287.90 |
1.79 |
2,391.25 |
1,575.00 |
37,741.13 |
| Ajanta Pharma Ltd |
3,012.15 |
1.42 |
3,314.80 |
2,335.00 |
37,632.48 |
| Rubicon Research Ltd |
1,169.65 |
-0.78 |
1,371.75 |
571.00 |
19,270.02 |
| ERIS Lifesciences Ltd |
1,372.65 |
0.56 |
1,909.55 |
1,237.90 |
19,020.44 |
|
|
|
|